Candriam Luxembourg S.C.A. reduced its position in shares of Puma Biotechnology Inc (NYSE:PBYI) by 68.3% during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 49,000 shares of the biopharmaceutical company’s stock after selling 105,500 shares during the period. Candriam Luxembourg S.C.A.’s holdings in Puma Biotechnology were worth $4,283,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently bought and sold shares of PBYI. FMR LLC boosted its stake in shares of Puma Biotechnology by 2.4% in the first quarter. FMR LLC now owns 3,540,729 shares of the biopharmaceutical company’s stock valued at $131,715,000 after buying an additional 81,410 shares in the last quarter. Wellington Management Group LLP boosted its stake in shares of Puma Biotechnology by 7.2% in the first quarter. Wellington Management Group LLP now owns 2,539,350 shares of the biopharmaceutical company’s stock valued at $94,464,000 after buying an additional 170,812 shares in the last quarter. Vanguard Group Inc. boosted its stake in shares of Puma Biotechnology by 4.4% in the first quarter. Vanguard Group Inc. now owns 2,428,909 shares of the biopharmaceutical company’s stock valued at $90,355,000 after buying an additional 101,722 shares in the last quarter. Redmile Group LLC boosted its stake in shares of Puma Biotechnology by 33.7% in the first quarter. Redmile Group LLC now owns 1,725,414 shares of the biopharmaceutical company’s stock valued at $64,185,000 after buying an additional 435,274 shares in the last quarter. Finally, Schroder Investment Management Group boosted its stake in shares of Puma Biotechnology by 22.8% in the first quarter. Schroder Investment Management Group now owns 803,926 shares of the biopharmaceutical company’s stock valued at $30,147,000 after buying an additional 149,205 shares in the last quarter. 80.98% of the stock is currently owned by institutional investors.

Shares of Puma Biotechnology Inc (NYSE PBYI) opened at 83.65 on Tuesday. The firm’s market cap is $3.09 billion. The company has a 50-day moving average of $88.12 and a 200 day moving average of $54.02. Puma Biotechnology Inc has a one year low of $28.35 and a one year high of $98.85.

Puma Biotechnology (NYSE:PBYI) last announced its earnings results on Wednesday, May 10th. The biopharmaceutical company reported ($1.97) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($2.06) by $0.09. On average, equities research analysts expect that Puma Biotechnology Inc will post ($8.43) EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Puma Biotechnology Inc (PBYI) Position Cut by Candriam Luxembourg S.C.A.” was first posted by Daily Political and is owned by of Daily Political. If you are accessing this article on another publication, it was illegally stolen and republished in violation of US & international trademark & copyright law. The legal version of this article can be read at https://www.dailypolitical.com/2017/08/08/puma-biotechnology-inc-pbyi-position-cut-by-candriam-luxembourg-s-c-a.html.

PBYI has been the topic of several research reports. J P Morgan Chase & Co reissued an “overweight” rating and set a $89.00 price target on shares of Puma Biotechnology in a research report on Wednesday, May 24th. Stifel Nicolaus reissued a “buy” rating and set a $118.00 price target (up previously from $105.00) on shares of Puma Biotechnology in a research report on Tuesday, July 18th. Zacks Investment Research cut shares of Puma Biotechnology from a “hold” rating to a “sell” rating in a research report on Tuesday, July 11th. Cowen and Company reissued a “market perform” rating on shares of Puma Biotechnology in a research report on Monday, May 22nd. Finally, Citigroup Inc. reissued a “buy” rating and set a $114.00 price target on shares of Puma Biotechnology in a research report on Tuesday, July 18th. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Puma Biotechnology has an average rating of “Buy” and an average target price of $101.75.

In other Puma Biotechnology news, SVP Richard Paul Bryce sold 5,000 shares of the company’s stock in a transaction that occurred on Monday, July 3rd. The stock was sold at an average price of $87.10, for a total value of $435,500.00. Following the transaction, the senior vice president now directly owns 34,237 shares of the company’s stock, valued at approximately $2,982,042.70. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, major shareholder Adage Capital Partners Gp, L.L sold 1,235,700 shares of the company’s stock in a transaction that occurred on Friday, May 26th. The shares were sold at an average price of $75.38, for a total value of $93,147,066.00. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 2,010,261 shares of company stock worth $159,425,452. 22.70% of the stock is currently owned by corporate insiders.

Puma Biotechnology Company Profile

Puma Biotechnology, Inc is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357.

Want to see what other hedge funds are holding PBYI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Puma Biotechnology Inc (NYSE:PBYI).

Institutional Ownership by Quarter for Puma Biotechnology (NYSE:PBYI)

Receive News & Ratings for Puma Biotechnology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology Inc and related companies with MarketBeat.com's FREE daily email newsletter.